Cargando…
A genetic polymorphism in P2RY(1) impacts response to clopidogrel in cats with hypertrophic cardiomyopathy
Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor. It is frequently used in cats with hypertrophic cardiomyopathy (HCM) to prevent thromboembolic complications. Howeve...
Autores principales: | Ueda, Yu, Li, Ronald H. L., Nguyen, Nghi, Ontiveros, Eric S., Kovacs, Samantha L., Oldach, Maureen S., Vernau, Karen M., Court, Michael H., Stern, Joshua A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206363/ https://www.ncbi.nlm.nih.gov/pubmed/34131167 http://dx.doi.org/10.1038/s41598-021-91372-3 |
Ejemplares similares
-
Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy
por: Oldach, Maureen S., et al.
Publicado: (2021) -
Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study
por: Oldach, Maureen S., et al.
Publicado: (2019) -
Circulating neutrophil extracellular traps in cats with hypertrophic cardiomyopathy and cardiogenic arterial thromboembolism
por: Li, Ronald H. L., et al.
Publicado: (2023) -
Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C
por: Stern, Joshua A., et al.
Publicado: (2023) -
Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet‐dependent thrombin generation in cats
por: Lo, Sara T., et al.
Publicado: (2023)